University of Mannheim   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Mannheim Germany (1967)

Organization Overview

First Clinical Trial
1995
NCT00002771
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Centre for Rhinology and Allergology of University Hospital Mannheim | Dep. Medicine II, University hospital Mannheim | Dep of Ophthalmology, University of Mannheim | III. Medizinische Klinik Mannheim | Onkologisches Zentrum III, Medizinische Klinik, Mannheim, Germany | Ralf Hofheinz | Skin Cancer Unit, German Cancer Research Center Heidelberg and Department of Dermatology, University Hospital of Mannheim, Mannheim, Germany | Universitaetsmedizin Mannheim | Universitätsmedizin Mannheim | Universitätsmedizin Mannheim, Tagestherapiezentrum am ITM | University Centre Mannheim and Heidelberg | University Hospital Mannheim | University Hospital Mannheim, Department of Surgery | University Medical Center Mannheim | University Medical Centre Mannheim | University of Mannheim, General Surgery | ZI Mannheim, Department of Clinical Psychology, RG Psychology and Neurobiology of Sleep and Memory

Active Ingredients

Drugs in Phase 4 Trials (9)

acetylsalicylic acid (aspirin) (1 trial)

clopidogrel (plavix) (1 trial)

dabigatran (pradaxa) (1 trial)

dopamine (intropin) (1 trial)

esomeprazole (nexium) (1 trial)

haloperidol (haldol) (2 trials)

lorazepam (ativan) (1 trial)

risperidone (risperdal) (1 trial)

rivaroxaban (xarelto) (1 trial)

Drugs in Phase 3 Trials (22)

allogeneic hematopoietic stem cells (Hemacord) (3 trials)

autologous bone marrow (2 trials)

autologous culture chondrocytes (Carticel) (2 trials)

busulfan (myleran) (2 trials)

capecitabine (xeloda) (2 trials)

cyclophosphamide (cytoxan) (2 trials)

cytarabine (cytosar-u) (3 trials)

docetaxel (taxotere) (2 trials)

etoposide (vepesid) (1 trial)

fluorouracil (efudex) (5 trials)

hydroxyurea (hydrea) (3 trials)

idarubicin (idamycin) (2 trials)

imatinib (gleevec) (2 trials)

interferon alpha-2b (Intron-A) (3 trials)

leucovorin (3 trials)

nimotuzumab (1 trial)

oxaliplatin (eloxatin) (4 trials)

peripheral blood hematopoietic cell (3 trials)

pertuzumab (perjeta) (1 trial)

sargramostim (leukine) (1 trial)

temozolomide (temodar) (1 trial)

trastuzumab (herceptin) (1 trial)

Drugs in Phase 2 Trials (9)

aflibercept (zaltrap) (1 trial)

dimethyl fumarate (tecfidera) (1 trial)

indocyanine green (ic-green) (1 trial)

paclitaxel (taxol) (1 trial)

pazopanib (votrient) (3 trials)

pentostatin (nipent) (1 trial)

ponatinib (iclusig) (1 trial)

p. pratense pollen extract (1 trial)

rituximab (rituxan) (1 trial)

Drugs in Phase 1 Trials (2)

cilengitide (1 trial)

triamcinolone (kenalog) (1 trial)

Drugs in Other Trials (6)

ethanol (1 trial)

fentanyl (Innovar) (1 trial)

lavender (1 trial)

orange (1 trial)

propofol (diprivan) (3 trials)

sevoflurane (ultane) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Angina Pectoris (Phase 4)

Angina, Stable (Phase 4)

Angina, Unstable (Phase 4)

Asthma (Phase 2)

Central Nervous System Neoplasms (Phase 1)

Colorectal Neoplasms (Phase 2)

Conjunctivitis (Phase 2)

Coronary Disease (Phase 4)

Dermatofibrosarcoma (Phase 2)

Diabetic Retinopathy (Phase 1)

Edema (Phase 1)

Gastroesophageal Reflux (Phase 4)

Gastrointestinal Stromal Tumors (Phase 2)

Glioblastoma (Phase 3)

Heartburn (Phase 4)

Hemangiosarcoma (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Chronic-Phase (Phase 3)

Liposarcoma (Phase 2)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Macular Edema (Phase 1)

Nervous System Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 3)

Rectal Neoplasms (Phase 3)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Sarcoma (Phase 2)

Schizophrenia (Phase 4)

Signs and Symptoms (Phase 2)

Stomach Neoplasms (Phase 3)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 33
  • # of Trial APIs: 48